Michael W. Deininger, MD, PhD

Research Interests

  • Chronic Myeloid Leukemia
  • Myeloproliferative Neoplasms
  • Leukemia Drug Resistance

Labs

Lab Website

Languages

  • English
  • German
  • Russian

Academic Information

  • Departments: Internal Medicine - Adjunct Professor, Oncological Sciences - Adjunct Professor
  • Divisions: Hematology/BMT

Board Certification

  • German Medical Association (Hematology and Medical Oncology)
  • German Medical Association (Internal Medicine)

Academic Bio

Michael Deininger, MD, PhD, is Professor and Chief of Hematology and Hematologic Malignancies in the Department of Internal Medicine and the Huntsman Cancer Institute (HCI) at the University of Utah. He has extensive experience treating patients with blood cancers. He has a particular interest in chronic myeloid leukemia (CML) and myeloproliferative neoplasms, a group of blood cancers related to leukemia. He sees patients at the University of Utah Huntsman Cancer Institute, Clinic 2C.

Dr. Deininger received his MD from the University of Würzburg Medical School, Germany, in 1990. Throughout his studies he was funded by the prestigious German Scholarship Foundation. He subsequently trained in Internal Medicine and Hematology/Oncology. In 1995 he obtained a grant to enroll in the PhD program at Imperial College, London. His thesis work focused on signal transduction and the potential use of imatinib (Gleevec) as molecularly targeted therapy for CML. After returning to Germany he completed a fellowship in stem cell transplantation at the University of Leipzig Medical Center. In 2002 he was recruited to the Division of Hematology and Medical Oncology at Oregon Health & Science University as an Assistant Professor. In 2007 he was promoted to the rank of Associate Professor and became the Head of the Hematologic Malignancies Section at OHSU. In August 2010 Dr. Deininger became the M.M. Wintrobe Professor of Medicine at the University of Utah and was appointed Chief of the Division of Hematology and Hematologic Malignancies. He was also appointed Senior Director for Transdisciplinary Research at Huntsman Cancer Institute. He was recently selected as the inaugural Director of the Huntsman Center for Excellence in Hematology and Hematologic Malignancies.

For questions regarding Dr. Deininger's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at http://www.huntsmancancer.org or (801) 587-4630.

Research Statement

As a clinician-scientist trained in hematology/oncology as well as molecular biology I have been interested in the biology and therapy of leukemia and myeloproliferative neoplasms (MPNs) for more than 20 years. I have led an extramurally funded laboratory for 15 years and have assembled a team of researchers and technicians that provides an excellent training environment. Our technical expertise encompasses molecular and cellular biology, chemistry and chemical biology, murine leukemia models and ex vivo analysis of primary leukemia cells (we have established a substantial biorepository with >20,000 samples from >1,200 patients). We have made a number of contributions to our field of study that have influenced how leukemia and MPNs are diagnosed, treated and monitored. I have played an important role in multiple clinical studies in MPNs, including chronic myeloid leukemia (CML) that contributed to the establishment of tyrosine kinase inhibitor (TKI) - based therapies as the standard of care. Today our work continues, focusing on novel therapeutic targets in leukemia, novel drugs to overcome TKI resistance in CML and other MPNs, and to understand the role of bone marrow micro environment for leukemogenesis. Over the years I have trained and mentored a number of pre- and postdoctoral students and clinical fellows. Several of my trainees have secured faculty positions at major academic institutions in Europe or the US, and have attracted extramural funding to establish their own independent research groups. Having been involved in research for many years the success of my trainees has become a key measure of my own achievement. I profoundly enjoy the opportunity to get inspired by young investigators setting out to develop their research careers and I am determined to help them on their path to independence.

Education History

Type School Degree
Fellowship University of Leipzig, Department of Hematology
Clinical Fellow
Doctoral Training Imperial College London
Ph.D.
Research Fellow Hammersmith Hospital, Department of Haematology
Research Fellow
Residency Institute of Medical Oncology and Haematology, Nürnberg General Hospital
Resident
Internship Katholische Stiftung Marienhospital Aachen
Intern
Professional Medical University of Würzburg
Medicine
M.D.
Certification Collegium Russicum
Russian Language
Certification
Doctoral Training University of Regensburg
M.D.

Global Impact

Education History

Type School Degree Country
Fellowship University of Leipzig, Department of Hematology
Clinical Fellow Germany
Doctoral Training Imperial College London
Ph.D. United Kingdom
Research Fellow Hammersmith Hospital, Department of Haematology
Research Fellow United Kingdom
Residency Institute of Medical Oncology and Haematology, Nürnberg General Hospital
Resident Germany
Internship Katholische Stiftung Marienhospital Aachen
Intern Germany
Professional Medical University of Würzburg
Medicine
M.D. Germany
Certification Collegium Russicum
Russian Language
Certification Russia
Doctoral Training University of Regensburg
M.D. Germany

Selected Publications

Journal Article

  1. Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, OHare T, Deininger MW (2020). Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia, 34(11), 2981-2991.
  2. Zhao H, Deininger MW (2020). Declaration of Bcr-Abl1 independence. Leukemia, 34(11), 2827-2836.
  3. Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, DeAngelo DJ, Gotlib J, Hobbs G, Maness L, Mead M, Metheny L, Mohan S, Moore JO, Naqvi K, Oehler V, Pallera AM, Patnaik M, Pratz K, Pusic I, Rose MG, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H (2020). Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(10), 1385-1415.
  4. Gerds AT, Gotlib J, Bose P, Deininger MW, Dunbar A, Elshoury A, George TI, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kuykendall AT, McMahon B, Mohan SR, Oehler V, Oh S, Pardanani A, Podoltsev N, Ranheim E, Rein L, Salit R, Snyder DS, Stein BL, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward DC, Bergman MA, Sundar H (2020). Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(9), 1248-1269.
  5. Silvestri G, Trotta R, Stramucci L, Ellis JJ, Harb JG, Neviani P, Wang S, Eisfeld AK, Walker CJ, Zhang B, Srutova K, Gambacorti-Passerini C, Pineda G, Jamieson CHM, Stagno F, Vigneri P, Nteliopoulos G, May PC, Reid AG, Garzon R, Roy DC, Moutuou MM, Guimond M, Hokland P, Deininger MW, Fitzgerald G, Harman C, Dazzi F, Milojkovic D, Apperley JF, Marcucci G, Qi J, Polakova KM, Zou Y, Fan X, Baer MR, Calabretta B, Perrotti D (2020). Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions. Blood Cancer Discov, 1(1), 48-67.
  6. Tavor S, Shalit T, Chapal Ilani N, Moskovitz Y, Livnat N, Groner Y, Barr H, Minden MD, Plotnikov A, Deininger MW, Kaushansky N, Shlush LI (2020). Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature. (Epub ahead of print) Haematologica.
  7. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Sauele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R (2020). European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia, 34(4), 966-984.
  8. Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann JM, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu SN, OHare T, Prchal JT, Deininger MW (2019). JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood, 134(26), 2388-2398.
  9. Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW (2019). Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med, 381(24), 2315-2326.
  10. Schneeweiss-Gleixner M, Byrgazov K, Stefanzl G, Berger D, Eisenwort G, Lucini CB, Herndlhofer S, Preuner S, Obrova K, Pusic P, Witzeneder N, Greiner G, Hoermann G, Sperr WR, Lion T, Deininger M, Valent P, Gleixner KV (2019). CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. (Epub ahead of print) EBioMedicine.
  11. Yan D, Pomicter AD, OHare T, Deininger MW (2019). ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation? Clin Cancer Res, 25(22), 6561-6563.
  12. Franzini A, Pomicter AD, Yan D, Khorashad JS, Tantravahi SK, Than H, Ahmann JM, OHare T, Deininger MW (2019). The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. Blood Adv, 3(20), 2949-2961.
  13. Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, Heinrich MC, Tyner JW, Rea D, Cayuela JM, Kim DW, Tognon CE, OHare T, Druker BJ, Deininger MW (2019). Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell, 36(4), 431-443.e5.
  14. Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lbbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstcker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM (2019). Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica, 104(10), 1935-1949.
  15. Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW (2019). Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood, 134(11), 867-879.
  16. Antelope O, Vellore NA, Pomicter AD, Patel AB, Van Scoyk A, Clair PM, Deininger MW, OHare T (2019). BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. Exp Hematol, 77, 36-40.e2.
  17. Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA (2019). Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol, 37(3), 240-252.
  18. Gilreath JA, Tchertanov L, Deininger MW (2019). Novel approaches to treating advanced systemic mastocytosis. Clin Pharmacol, 11, 77-92.
  19. Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Crescenzo R, Mamolo C, Reisman A, Hochhaus A, Brmmendorf TH, BFORE Study Investigators (2019). Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. J Cancer Res Clin Oncol, 145(6), 1589-1599.
  20. Patel AB, Miles RR, Deininger MW (2019). Lysozyme nephropathy in chronic myelomonocytic leukemia. Clin Case Rep, 7(6), 1263-1264.
  21. Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M (2019). Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. Leuk Res, 79, 38-44.
  22. Niyongere S, Lucas N, Zhou JM, Sansil S, Pomicter AD, Balasis ME, Robinson J, Kroeger J, Zhang Q, Zhao YL, Ball M, Komrokji R, List A, Deininger MW, Fridley BL, Santini V, Solary E, Padron E (2019). Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia, 33(1), 205-216.
  23. Heaton WL, Senina AV, Pomicter AD, Salama ME, Clair PM, Yan D, Bell RN, Gililland JM, Prchal JT, OHare T, Deininger MW (2018). Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion. Leukemia, 32(11), 2399-2411.
  24. Than H, Qiao Y, Huang X, Yan D, Khorashad JS, Pomicter AD, Kovacsovics TJ, Marth GT, OHare T, Deininger MW (2018). Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective. Leukemia, 32(9), 2049-2054.
  25. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Mller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM (2018). Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood, 132(4), 393-404.
  26. Deininger MWN, Tyner JW, Solary E (2017). Turning the tide in myelodysplastic/myeloproliferative neoplasms. Nat Rev Cancer, 17(7), 425-440.
  27. Carey A, Edwards DK 5th, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A (2017). Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. Cell Rep, 18(13), 3204-3218.
  28. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, OBrien SG, Druker BJ, IRIS Investigators (2017). Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med, 376(10), 917-927.
  29. Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H (2017). Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol, 10(1), 55.
  30. Gupta V, Mesa RA, Deininger MW, Rivera CE, Sirhan S, Brachmann CB, Collins H, Kawashima J, Xin Y, Verstovsek S (2017). A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica, 102(1), 94-102.
  31. Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H (2016). Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 14(12), 1572-1611.
  32. Khorashad JS, Tantravahi SK, Yan D, Mason CC, Qiao Y, Eiring AM, Gligorich K, Hein T, Pomicter AD, Reid AG, Kelley TW, Marth GT, OHare T, Deininger MW (2016). Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. Leukemia, 30(11), 2275-2279.
  33. Tantravahi SK, Szankasi P, Khorashad JS, Dao KH, Kovacsovics T, Kelley TW, Deininger MW (2016). A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza(R)) in patients with chronic myelomonocytic leukemia. Leuk Lymphoma, 57(10), 2441-4.
  34. Wagle M, Eiring AM, Wongchenko M, Lu S, Guan Y, Wang Y, Lackner M, Amler L, Hampton G, Deininger MW, OHare T, Yan Y (2016). A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Leukemia, 30(7), 1493-501.
  35. Zabriskie MS, Eide CA, Yan D, Vellore NA, Pomicter AD, Savage SL, Druker BJ, Deininger MW, OHare T (2016). Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia. Leukemia, 30(6), 1418-21.
  36. Khoury HJ, Goldberg SL, Mauro MJ, Stone RM, Deininger MW, Bradley-Garelik MB, Mohamed H, Guilhot F (2016). Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk, 16(6), 341-349.e1.
  37. Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW (2016). Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol, 17(5), 612-21.
  38. Ali AM, Gomez-Biagi RF, Rosa DA, Lai PS, Heaton WL, Park JS, Eiring AM, Vellore NA, de Araujo ED, Ball DP, Shouksmith AE, Patel AB, Deininger MW, OHare T, Gunning PT (2016). Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. ChemMedChem, 11(8), 850-61.
  39. Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, Druker BJ, Gotlib J, OHare T, Deininger MW (2016). Age-related mutations and chronic myelomonocytic leukemia. Leukemia, 30(4), 906-13.
  40. Patel AB, Vellore NA, Deininger MW (2016). New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape. Clin Cancer Res, 22(5), 1037-47.
  41. Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Mller MC, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hochhaus A, Hughes TP, Rivera VM, Branford S (2016). Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood, 127(6), 703-12.
  42. Eiring AM, Khorashad JS, Anderson DJ, Yu F, Redwine HM, Mason CC, Reynolds KR, Clair PM, Gantz KC, Zhang TY, Pomicter AD, Kraft IL, Bowler AD, Johnson K, Partlin MM, OHare T, Deininger MW (2015). beta-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia, 29(12), 2328-37.
  43. Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, Deininger MW, OHare T, Druker BJ (2015). Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proc Natl Acad Sci U S A, 112(39), E5381-90.
  44. Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S (2015). The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood, 126(13), 1551-4.
  45. Zabriskie MS, Vellore NA, Gantz KC, Deininger MW, OHare T (2015). Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1. Leukemia, 29(9), 1939-42.
  46. Woessner DW, Eiring AM, Bruno BJ, Zabriskie MS, Reynolds KR, Miller GD, OHare T, Deininger MW, Lim CS (2015). A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia. Leukemia, 29(8), 1668-75.
  47. Mughal TI, Barbui T, Abdel-Wahab O, Kralovics R, Jamieson C, Kvasnicka HM, Mullaly A, Rampal R, Mesa R, Kiladjian JJ, Deininger M, Prchal J, Hehlmann R, Saglio G, Van Etten RA (2015). Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leuk Lymphoma, 56(7), 1938-48.
  48. Pomicter AD, Eiring AM, Senina AV, Zabriskie MS, Marvin JE, Prchal JT, OHare T, Deininger MW (2015). Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. Exp Hematol, 43(7), 537-45.e1-11.
  49. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H (2015). Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica, 100(4), 479-88.
  50. Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, Yu F, Kraft IL, Pomicter AD, Reynolds KR, Iovino AJ, Zabriskie MS, Heaton WL, Tantravahi SK, Kauffman M, Shacham S, Chenchik A, Bonneau K, Ullman KS, OHare T, Deininger MW (2015). shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood, 125(11), 1772-81.
  51. Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Moriggl R, Wilson DJ, Baron R, OHare T, Gunning PT, Deininger MW (2015). Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia, 29(3), 586-597.
  52. Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA (2015). Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance. Nat Med, 21(1), 71-5.
  53. Deininger MW (2015). Diagnosing and managing advanced chronic myeloid leukemia. Am Soc Clin Oncol Educ Book, 35, e381-8.
  54. Deininger MW (2015). Molecular monitoring in CML and the prospects for treatment-free remissions. Hematology Am Soc Hematol Educ Program, 2015(1), 257-63.
  55. Tantravahi SK, Salama ME, Deininger MN (2014). Aggressive systemic mastocytosis mimicking lymphoma: description of an unusual presentation and review of the literature on current management strategies. Leuk Lymphoma, 55(12), 2963-6.
  56. Agarwal A, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, Fleischman AG, Duquesnes N, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, OHare T, Roberts JM, Druker BJ, Deininger MW (2014). BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. Blood, 124(22), 3260-73.
  57. OBrien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, Curtin P, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H (2014). Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw, 12(11), 1590-610.
  58. Eiring AM, Deininger MW (2014). Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. Genome Biol, 15(9), 461.
  59. Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernandez-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, OHare T (2014). BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell, 26(3), 428-442.
  60. Stenehjem DD, Albright F, Kuo KL, Raimundo K, Bauer H, Shami PJ, Deininger MW, Chen L, Brixner DI (2014). Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database. J Natl Compr Canc Netw, 12(8), 1113-21.
  61. Deininger M (2014). The current status of ponatinib in the treatment of chronic myeloid leukemia. Clin Adv Hematol Oncol, 12(5), 329-31.
  62. Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C (2014). Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica, 99(2), 292-8.
  63. Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJ (2014). Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol, 164(2), 223-32.
  64. Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, Muller MC, Radich JP, Shah NP (2014). Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res, 38(1), 10-20.
  65. Jabbour E, Ottmann OG, Deininger M, Hochhaus A (2014). Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica, 99(1), 7-18.
  66. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM (2013). Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica, 98(12), 1865-71.
  67. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H (2013). A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med, 369(19), 1783-96.
  68. OBrien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Pinilla-Ibarz J, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H (2013). Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Netw, 11(11), 1327-40.
  69. Corbin AS, OHare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW (2013). KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res, 73(18), 5775-86.
  70. Sonnichsen D, Dorer DJ, Cortes J, Talpaz M, Deininger MW, Shah NP, Kantarjian HM, Bixby D, Mauro MJ, Flinn IW, Litwin J, Turner CD, Haluska FG (2013). Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemother Pharmacol, 71(6), 1599-607.
  71. OHare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, Latocha DH, Johnson KJ, You H, Luo J, Riddle SM, Marks BD, Vogel KW, Koop DR, Apgar J, Tyner JW, Deininger MW, Druker BJ (2013). Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. Cancer Res, 73(11), 3356-70.
  72. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW (2013). Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med, 368(19), 1781-90.
  73. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM (2013). The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol, 161(4), 508-16.
  74. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S (2013). Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol, 31(10), 1285-92.
  75. Melkus M, Bennaceur-Griscelli A, Valogne Y, Flamant S, Chomel JC, Sorel N, Bonnet ML, Deininger MW, Mitjavila-Garcia MT, Turhan AG (2013). Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model. Exp Hematol, 41(4), 335-45.e3.
  76. Kurokawa M, Ito T, Yang CS, Zhao C, Macintyre AN, Rizzieri DA, Rathmell JC, Deininger MW, Reya T, Kornbluth S (2013). Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells. Proc Natl Acad Sci U S A, 110(6), 2300-5.
  77. Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, Alikian M, Reid AG, Foroni L, Marin D, Druker BJ, OHare T, Deininger MW (2013). BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood, 121(3), 489-98.
  78. Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, OHare T, Druker BJ, Loriaux MM (2013). Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res, 73(1), 285-96.
  79. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, OHare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M (2012). Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med, 367(22), 2075-88.
  80. Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ (2012). A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood, 120(19), 3898-905.
  81. Agarwal A, Fleischman AG, Petersen CL, MacKenzie R, Luty S, Loriaux M, Druker BJ, Woltjer RL, Deininger MW (2012). Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Blood, 120(13), 2658-68.
  82. Deininger M (2012). Stem cell persistence in chronic myeloid leukemia. Leuk Suppl, 1(Suppl 2), S46-8.
  83. Chang KH, Sanchez-Aguilera A, Shen S, Sengupta A, Madhu MN, Ficker AM, Dunn SK, Kuenzi AM, Arnett JL, Santho RA, Agirre X, Perentesis JP, Deininger MW, Zheng Y, Bustelo XR, Williams DA, Cancelas JA (2012). Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival. Blood, 120(4), 800-11.
  84. Ridges S, Heaton WL, Joshi D, Choi H, Eiring A, Batchelor L, Choudhry P, Manos EJ, Sofla H, Sanati A, Welborn S, Agarwal A, Spangrude GJ, Miles RR, Cox JE, Frazer JK, Deininger M, Balan K, Sigman M, Muschen M, Perova T, Johnson R, Montpellier B, Guidos CJ, Jones DA, Trede NS (2012). Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood, 119(24), 5621-31.
  85. Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, OHare T, Druker BJ, Deininger MW (2012). Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia, 26(5), 1140-3.
  86. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 366(9), 799-807.
  87. Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, OHare T, Druker BJ, Bagby GC, Deininger MW (2011). TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood, 118(24), 6392-8.
  88. OHare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ (2011). The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood, 118(19), 5250-4.
  89. Woessner DW, Lim CS, Deininger MW (2011). Development of an effective therapy for chronic myelogenous leukemia. Cancer J, 17(6), 477-86.
  90. Terry EN, Gann PH, Molokie R, Deininger M, Diamond AM (2011). Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment. Leuk Res, 35(6), 831-3.
  91. Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, OHare T, Druker BJ (2011). The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res, 71(9), 3189-95.
  92. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, DEmilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Piazza R, Valsecchi MG, Kim DW (2011). Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst, 103(7), 553-61.
  93. Deininger M (2011). Hematology: curing CML with imatinib--a dream come true? Nat Rev Clin Oncol, 8(3), 127-8.
  94. OHare T, Deininger MW, Eide CA, Clackson T, Druker BJ (2011). Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res, 17(2), 212-21.
  95. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA (2011). CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood, 117(2), 591-4.
  96. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ (2011). Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest, 121(1), 396-409.
  97. Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW (2010). BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood, 116(17), 3278-85.
  98. La Rosee P, Deininger MW (2010). Resistance to imatinib: mutations and beyond. Semin Hematol, 47(4), 335-43.
  99. Seo JH, Wood LJ, Agarwal A, OHare T, Elsea CR, Griswold IJ, Deininger MW, Imamoto A, Druker BJ (2010). A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors. Cancer Res, 70(18), 7325-35.
  100. Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, Mori M, Heinrich MC, Deininger MW, Druker BJ, Loriaux MM (2010). MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res, 70(15), 6233-7.
  101. Bright SA, Campiani G, Deininger MW, Lawler M, Williams DC, Zisterer DM (2010). Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment. Biochem Pharmacol, 80(1), 31-8.
  102. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW (2010). CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 115(25), 5232-40.
  103. Bright SA, McElligott AM, OConnell JW, OConnor L, Carroll P, Campiani G, Deininger MW, Conneally E, Lawler M, Williams DC, Zisterer DM (2010). Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. Utah Special Educator, 102(10), 1474-82.
  104. Deininger M (2010). Chronic myelogenous leukemia therapy beyond imatinib. Clin Adv Hematol Oncol, 8(3), 178-80.
  105. Lange T, Deininger MW (2010). Molecular diagnostics in chronic myeloid leukemia. Expert Opin Med Diagn, 4(2), 113-24.
  106. McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, Yochum G, Wilmot B, Turpaz Y, Pillai R, Druker BJ, Snead JL, MacPartlin M, OBrien SG, Melo JV, Lange T, Harrington CA, Deininger MW (2010). A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood, 115(2), 315-25.
  107. OHare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (2009). AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 16(5), 401-12.
  108. Snead JL, OHare T, Adrian LT, Eide CA, Lange T, Druker BJ, Deininger MW (2009). Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood, 114(16), 3459-63.
  109. Johnson KJ, Griswold IJ, OHare T, Corbin AS, Loriaux M, Deininger MW, Druker BJ (2009). A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice. PLoS ONE, 4(10), e7439.
  110. Aichberger KJ, Fleischman AG, Deininger MW (2009). Same mutation, different allele. Blood, 114(14), 2853-4.
  111. Press RD, Willis SG, Laudadio J, Mauro MJ, Deininger MW (2009). Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood, 114(13), 2598-605.
  112. Mauro MJ, Deininger MW (2009). Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol, 22(3), 409-29.
  113. Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-Gonzalez L, Esparis-Ogando A, del Peso Ovalle L, Bellon-Echeverria I, de la Cruz-Morcillo MA, Galan Moya EM, Moreno Gimeno I, Gomez JC, Deininger MW, Pandiella A, Sanchez Prieto R (2009). ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy. PLoS ONE, 4(7), e6124.
  114. Tyner JW, Rutenberg-Schoenberg ML, Erickson H, Willis SG, OHare T, Deininger MW, Druker BJ, Loriaux MM (2009). Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation. Leukemia, 23(7), 1345-8.
  115. Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, OHare T, Heinrich MC, Druker BJ (2009). RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A, 106(21), 8695-700.
  116. Tyner JW, Erickson H, Deininger MW, Willis SG, Eide CA, Levine RL, Heinrich MC, Gattermann N, Gilliland DG, Druker BJ, Loriaux MM (2009). High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood, 113(8), 1749-55.
  117. Tyner JW, Loriaux MM, Erickson H, Eide CA, Deininger J, MacPartlin M, Willis SG, Lange T, Druker BJ, Kovacsovics T, Maziarz R, Gattermann N, Deininger MW (2009). High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia. Leukemia, 23(2), 406-9.
  118. Oehler VG, Qin J, Ramakrishnan R, Facer G, Ananthnarayan S, Cummings C, Deininger M, Shah N, McCormick F, Willis S, Daridon A, Unger M, Radich JP (2009). Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia, 23(2), 396-9.
  119. Agarwal A, Eide CA, Harlow A, Corbin AS, Mauro MJ, Druker BJ, Corless CL, Heinrich MC, Deininger MW (2008). An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. Leukemia, 22(12), 2269-72.
  120. Pelz-Ackermann O, Cross M, Pfeifer H, Deininger M, Wang SY, Al-Ali HK, Niederwieser D, Lange T (2008). Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR. Leukemia, 22(12), 2288-91.
  121. Agarwal A, Bumm TG, Corbin AS, OHare T, Loriaux M, VanDyke J, Willis SG, Deininger J, Nakayama KI, Druker BJ, Deininger MW (2008). Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood, 112(5), 1960-70.
  122. MacPartlin M, Smith AM, Druker BJ, Honigberg LA, Deininger MW (2008). Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia, 22(7), 1354-60.
  123. Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A (2008). Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol, 26(19), 3204-12.
  124. OHare T, Eide CA, Deininger MW (2008). New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs, 17(6), 865-78.
  125. Sherbenou DW, Hantschel O, Turaga L, Kaupe I, Willis S, Bumm T, Press RD, Superti-Furga G, Druker BJ, Deininger MW (2008). Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia, 22(6), 1184-90.
  126. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Muller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM (2008). Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia, 22(6), 1200-6.
  127. Loriaux MM, Levine RL, Tyner JW, Frohling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, Heinrich MC, Deininger MW, Gilliland DG, Druker BJ (2008). High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood, 111(9), 4788-96.
  128. Larson RA, Druker BJ, Guilhot F, OBrien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y, IRIS International Randomized Interferon vs STI571 Study Group (2008). Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood, 111(8), 4022-4028.
  129. OHare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, Holme K, Jessen KA, Tang C, Lewis HA, Romero RD, Burley SK, Deininger MW (2008). SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci U S A, 105(14), 5507-12.
  130. Laudadio J, Deininger MW, Mauro MJ, Druker BJ, Press RD (2008). An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn, 10(2), 177-80.
  131. Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, Erickson H, Corbin AS, OHare T, Heinrich MC, Deininger MW, Druker BJ (2008). RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood, 111(4), 2238-45.
  132. Nardi V, Raz T, Cao X, Wu CJ, Stone RM, Cortes J, Deininger MW, Church G, Zhu J, Daley GQ (2008). Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene, 27(6), 775-82.
  133. Frohling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Dohner H, Dohner K, Ebert BL, Teckie S, Golub TR, Jiang J, Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker BJ, Gilliland DG (2007). Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell, 12(6), 501-13.
  134. Bao F, Polk P, Nordberg ML, Veillon DM, Sun A, Deininger M, Murray D, Andersson BS, Munker R (2007). Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res, 31(11), 1511-20.
  135. Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, Druker BJ, Deininger MW (2007). A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res, 13(20), 6136-43.
  136. Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjian H, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, Druker BJ, Guilhot F (2007). The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer, 110(7), 1509-19.
  137. Blasdel C, Egorin MJ, Lagattuta TF, Druker BJ, Deininger MW (2007). Therapeutic drug monitoring in CML patients on imatinib. Blood, 110(5), 1699-701; author reply 1701.
  138. OHare T, Eide CA, Deininger MW (2007). Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia. Clin Lymphoma Myeloma, 7 Suppl 3, S120-30.
  139. Sherbenou DW, Wong MJ, Humayun A, McGreevey LS, Harrell P, Yang R, Mauro M, Heinrich MC, Press RD, Druker BJ, Deininger MW (2007). Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia, 21(3), 489-93.
  140. Druker BJ, Guilhot F, OBrien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355(23), 2408-17.
  141. Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW (2006). Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res, 66(23), 11156-65.
  142. La Rosee P, Jia T, Demehri S, Hartel N, de Vries P, Bonham L, Hollenback D, Singer JW, Melo JV, Druker BJ, Deininger MW (2006). Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. Clin Cancer Res, 12(21), 6540-6.
  143. Bradeen HA, Eide CA, OHare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW (2006). Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood, 108(7), 2332-8.
  144. Walters DK, Goss VL, Stoffregen EP, Gu TL, Lee K, Nardone J, McGreevey L, Heinrich MC, Deininger MW, Polakiewicz R, Druker BJ (2006). Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leuk Res, 30(9), 1097-104.
  145. Griswold IJ, MacPartlin M, Bumm T, Goss VL, OHare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW (2006). Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol, 26(16), 6082-93.
  146. Walters DK, Mercher T, Gu TL, OHare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, Boggon TJ, Heinrich MC, Deininger MW, Polakiewicz RD, Gilliland DG, Druker BJ (2006). Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell, 10(1), 65-75.
  147. Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S, Mori M, Mauro MJ, Deininger MW, Druker BJ (2006). BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood, 107(11), 4250-6.
  148. Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J, Maziarz R, Olavarria E, Verdonck L, Schaefer K, Boque C, Faber E, Nagler A, Pogliani E, Russell N, Volin L, Schanz U, Doelken G, Kiehl M, Fauser A, Druker B, Sureda A, Iacobelli S, Brand R, Krahl R, Lange T, Hochhaus A, Gratwohl A, Kolb H, Niederwieser D (2006). The effect of prior exposure to imatinib on transplant-related mortality. Haematologica, 91(4), 452-9.
  149. Demehri S, Corbin A, Loriaux M, Druker BJ, Deininger MW (2006). Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia. Exp Hematol, 34(3), 284-8.
  150. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC (2006). Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res, 66(1), 473-81.
  151. Lange T, Park B, Willis SG, Deininger MW (2005). BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy? Cell Cycle, 4(12), 1761-6.
  152. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW (2005). The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood, 106(10), 3377-9.
  153. Chuah C, Barnes DJ, Kwok M, Corbin A, Deininger MW, Druker BJ, Melo JV (2005). Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. Leukemia, 19(11), 1896-904.
  154. Crossman LC, OHare T, Lange T, Willis SG, Stoffregen EP, Corbin AS, OBrien SG, Heinrich MC, Druker BJ, Middleton PG, Deininger MW (2005). A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib. Leukemia, 19(11), 1859-62.
  155. Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P (2005). Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res, 65(20), 9436-44.
  156. OHare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ (2005). Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res, 11(19 Pt 1), 6987-93.
  157. Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, Druker BJ, Deininger MW (2005). High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood, 106(6), 2128-37.
  158. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE (2005). hOCT 1 and resistance to imatinib. Blood, 106(3), 1133-4; author reply 1134.
  159. Lange T, Bumm T, Mueller M, Otto S, Al-Ali HK, Grommisch L, Musiol S, Franke C, Krahl R, Niederwieser D, Deininger MW (2005). Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation. Leukemia, 19(7), 1262-5.
  160. Corbin AS, Demehri S, Griswold IJ, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Shakespeare WC, Snodgrass J, Wardwell S, Dalgarno D, Iuliucci J, Sawyer TK, Heinrich MC, Druker BJ, Deininger MW (2005). In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood, 106(1), 227-34.
  161. OHare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ (2005). In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res, 65(11), 4500-5.
  162. Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak S, Sperr WR, Esterbauer H, Wagner O, Marosi C, Pickl WF, Deininger M, Weisberg E, Druker BJ, Griffin JD, Sillaber C, Valent P (2005). Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J, 19(8), 960-2.
  163. Crossman LC, Mori M, Hsieh YC, Lange T, Paschka P, Harrington CA, Krohn K, Niederwieser DW, Hehlmann R, Hochhaus A, Druker BJ, Deininger MW (2005). In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica, 90(4), 459-64.
  164. Demehri S, Paschka P, Schultheis B, Lange T, Koizumi T, Sugimoto T, Branford S, Lim LC, Kegel T, Martinelli G, Hochhaus A, Druker BJ, Deininger MW (2005). e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants? Leukemia, 19(4), 681-4.
  165. Walters DK, Stoffregen EP, Heinrich MC, Deininger MW, Druker BJ (2005). RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood, 105(7), 2952-4.
  166. Deininger MW, Holyoake TL (2005). Can we afford to let sleeping dogs lie? 105(5), 1840-1.
  167. Corbin AS, Griswold IJ, La Rosee P, Yee KW, Heinrich MC, Reimer CL, Druker BJ, Deininger MW (2004). Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood, 104(12), 3754-7.
  168. Grossmann AH, Kolibaba KS, Willis SG, Corbin AS, Langdon WS, Deininger MW, Druker BJ (2004). Catalytic domains of tyrosine kinases determine the phosphorylation sites within c-Cbl. FEBS Lett, 577(3), 555-62.
  169. Griswold IJ, Shen LJ, La Rosee P, Demehri S, Heinrich MC, Braziel RM, McGreevey L, Haley AD, Giese N, Druker BJ, Deininger MW (2004). Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood, 104(9), 2912-8.
  170. OHare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ (2004). Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood, 104(8), 2532-9.
  171. Lange T, Deininger M, Brand R, Hegenbart U, Al-Ali H, Krahl R, Poenisch W, Uharek L, Leiblein S, Gentilini C, Petersdorf E, Storb RF, Niederwieser D (2004). BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning. Leukemia, 18(9), 1468-75.
  172. Mauro MJ, Loriaux M, Deininger MW (2004). Ph-positive and -negative myeloproliferative syndromes may co-exist. Leukemia, 18(7), 1305-7.
  173. Melo JV, Deininger MW (2004). Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation. Hematol Oncol Clin North Am, 18(3), 545-68, vii-viii.
  174. Deininger MW, McGreevey L, Willis S, Bainbridge TM, Druker BJ, Heinrich MC (2004). Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia, 18(4), 864-71.
  175. Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, Kohler T, Krahl R, Niederwieser D, Deininger MW (2004). Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Haematologica, 89(1), 49-57.
  176. Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Muller C, Niederwieser D, Druker BJ, Deininger MW (2004). High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J, 5(1), 55-60.
  177. Gaston I, Johnson KJ, Oda T, Bhat A, Reis M, Langdon W, Shen L, Deininger MW, Druker BJ (2004). Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl. Exp Hematol, 32(1), 113-21.
  178. La Rosee P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, Mauro MM, Melo JV, Deininger MW, Druker BJ (2004). In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood, 103(1), 208-15.
  179. Dinulescu DM, Wood LJ, Shen L, Loriaux M, Corless CL, Gross AW, Ren R, Deininger MW, Druker BJ (2003). c-CBL is not required for leukemia induction by Bcr-Abl in mice. Oncogene, 22(55), 8852-60.
  180. Muller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, Neubauer A, Fischer T, Hossfeld DK, Schneller F, Krause SW, Nerl C, Sayer HG, Ottmann OG, Waller C, Aulitzky W, le Coutre P, Freund M, Merx K, Paschka P, Konig H, Kreil S, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A (2003). Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia, 17(12), 2392-400.
  181. Tipping AJ, Deininger MW, Goldman JM, Melo JV (2003). Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol, 31(11), 1073-80.
  182. Lange T, Niederwieser DW, Deininger MW (2003). Residual disease in chronic myeloid leukemia after induction of molecular remission. N Engl J Med, 349(15), 1483-4.
  183. Reinhold U, Hennig E, Leiblein S, Niederwieser D, Deininger MW (2003). FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib. Leukemia, 17(10), 1925-9.
  184. Wiedmann M, Kreth F, Feisthammel J, Deininger M, Mossner J, Caca K (2003). Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer? Anticancer Drugs, 14(9), 751-60.
  185. Huntly BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C, Byrne J, Brizard A, Niederwieser D, Freeman-Edward J, Cuthbert G, Bown N, Clark RE, Nacheva EP, Green AR, Deininger MW (2003). Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood, 102(6), 2205-12.
  186. Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J, Lipton J, Vitek A, Michallet M, Siegert W, Ullmann A, Wassmann B, Niederwieser D, Fischer T (2003). Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia, 17(9), 1707-12.
  187. Rumpel M, Friedrich T, Deininger MW (2003). Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase. Blood, 101(11), 4641-3.
  188. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW (2003). Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood, 101(11), 4611-4.
  189. Lange T, Gunther C, Kohler T, Krahl R, Musiol S, Leiblein S, Al-Ali HK, van Hoomissen I, Niederwieser D, Deininger MW (2003). High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood, 101(6), 2152-5.
  190. Bumm T, Muller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E, Leiblein S, Franke C, Hennig E, Friedrich T, Krahl R, Niederwieser D, Deininger MW (2003). Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood, 101(5), 1941-9.
  191. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Ponisch W, Anasetti C, Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF (2003). Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood, 101(4), 1620-9.
  192. La Rosee P, Shen L, Stoffregen EP, Deininger M, Druker BJ (2003). No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). Hematol J, 4(6), 413-9.
  193. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ (2002). Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res, 62(24), 7149-53.
  194. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, OBrien SG (2002). A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood, 100(6), 1965-71.
  195. Al-Ali HK, Leiblein S, Kovacs I, Hennig E, Niederwieser D, Deininger M (2002). CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfall. Blood, 100(3), 1092-3.
  196. Huntly BJ, Bench AJ, Delabesse E, Reid AG, Li J, Scott MA, Campbell L, Byrne J, Pinto E, Brizard A, Niedermeiser D, Nacheva EP, Guilhot F, Deininger M, Green AR (2002). Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood, 99(12), 4547-53.
  197. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, OBrien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ (2002). Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 99(10), 3530-9.
  198. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL (2002). Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 99(6), 1928-37.
  199. Khler T, Schill C, Deininger MW, Krahl R, Borchert S, Hasenclever D, Leiblein S, Wagner O, Niederwieser D (2002). High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). Leukemia, 16(1), 22-9.
  200. Vieira SA, Deininger MW, Sorour A, Sinclair P, Foroni L, Goldman JM, Melo JV (2001). Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene. Genes Chromosomes Cancer, 32(4), 353-63.
  201. Deininger MW, Vieira SA, Parada Y, Banerji L, Lam EW, Peters G, Mahon FX, Kohler T, Goldman JM, Melo JV (2001). Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer Res, 61(21), 8005-13.
  202. Deininger M, Ponisch W, Krahl R, Leiblein S, Edel E, Lange T, Fiedler F, Freund M, Franke A, Pasold R, von Grunhagen U, Herold M, Dolken G, Hoffmann FA, Uhle R, Schultze W, Steglich J, Schwarzer A, Richter P, Winkelmann C, Kettner E, Dachselt K, Subert R, Schwalbe E, Doepper J, Helbig W, Niederwieser D (2001). Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens. Bone Marrow Transplant, 27(11), 1125-32.
  203. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV (2000). Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 96(3), 1070-9.
  204. Deininger M, Lehmann T, Krahl R, Hennig E, Muller C, Niederwieser D (2000). No evidence for persistence of BCR-ABL-positive cells in patients in molecular remission after conventional allogenic transplantation for chronic myeloid leukemia. Blood, 96(2), 779-80.
  205. Marley SB, Deininger MW, Davidson RJ, Goldman JM, Gordon MY (2000). The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol, 28(5), 551-7.
  206. Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV (2000). BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res, 60(7), 2049-55.
  207. Gora-Tybor J, Deininger MW, Goldman JM, Melo JV (1998). The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL. Br J Haematol, 103(3), 716-20.
  208. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV (1998). The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood, 92(9), 3362-7.
  209. Deininger MW, Goldman JM (1998). Chronic myeloid leukemia. Curr Opin Hematol, 5(4), 302-8.
  210. Deininger MW, Bose S, Gora-Tybor J, Yan XH, Goldman JM, Melo JV (1998). Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation. Cancer Res, 58(3), 421-5.
  211. Deininger MW, Goldman JM, Lydon N, Melo JV (1997). The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 90(9), 3691-8.

Review

  1. Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ (2016). Chronic myeloid leukemia: reminiscences and dreams. [Review]. Haematologica, 101(5), 541-58.
  2. Moslehi JJ, Deininger M (2015). Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. [Review]. J Clin Oncol, 33(35), 4210-8.
  3. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013). European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. [Review]. Blood, 122(6), 872-84.
  4. OHare T, Zabriskie MS, Eiring AM, Deininger MW (2012). Pushing the limits of targeted therapy in chronic myeloid leukaemia. [Review]. Nat Rev Cancer, 12(8), 513-26.
  5. Deininger MW, Manley P (2012). What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML? [Review]. Leuk Res, 36(3), 253-61.
  6. Shami PJ, Deininger M (2012). Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. [Review]. Leukemia, 26(2), 214-24.
  7. Khorashad JS, Deininger MW (2011). Selection of therapy: rational decisions based on molecular events. [Review]. Hematol Oncol Clin North Am, 25(5), 1009-23, vi.
  8. Eiring AM, Khorashad JS, Morley K, Deininger MW (2011). Advances in the treatment of chronic myeloid leukemia. [Review]. BMC Medicine, 9, 99.
  9. Mitchell B, Deininger M (2011). Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia. [Review]. Leuk Lymphoma, 52 Suppl 1, 4-11.
  10. Jabbour E, Deininger M, Hochhaus A (2011). Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. [Review]. Leukemia, 25(2), 201-10.
  11. Traer E, Deininger MW (2010). How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia. [Review]. Clin Lymphoma Myeloma Leuk, 10 Suppl 1, S20-6.
  12. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R (2009). Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. [Review]. J Clin Oncol, 27(35), 6041-51.
  13. OHare T, Deininger MW (2008). Toward a cure for chronic myeloid leukemia. [Review]. Clin Cancer Res, 14(24), 7971-4.
  14. Deininger MW (2008). Nilotinib. [Review]. Clin Cancer Res, 14(13), 4027-31.
  15. Valent P, Deininger M (2008). Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia. [Review]. Leuk Lymphoma, 49(4), 604-9.
  16. Snead JL, OHare T, Eide CA, Deininger MW (2008). New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided? [Review]. Clin Lymphoma Myeloma, 8 Suppl 3, S107-17.
  17. Deininger M (2008). Resistance and relapse with imatinib in CML: causes and consequences. [Review]. J Natl Compr Canc Netw, 6 Suppl 2, S11-S21.
  18. Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T, Mauro M, Radich J, Ottmann O, Cortes J (2008). Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. [Review]. Semin Oncol, 35(1 Suppl 1), S1-17; quiz S18-20.
  19. Deininger MW (2008). Milestones and monitoring in patients with CML treated with imatinib. [Review]. Hematology Am Soc Hematol Educ Program, 419-26.
  20. Deininger MW (2008). Chronic myeloid leukemia: an historical perspective. [Review]. Hematology Am Soc Hematol Educ Program, 418.
  21. OHare T, Eide CA, Deininger MW (2007). Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. [Review]. Blood, 110(7), 2242-9.
  22. Deininger MW (2007). Optimizing therapy of chronic myeloid leukemia. [Review]. Exp Hematol, 35(4 Suppl 1), 144-54.
  23. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R (2006). Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. [Review]. Blood, 108(6), 1809-20.
  24. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM (2006). Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. [Review]. Blood, 108(1), 28-37.
  25. Mauro MJ, Deininger MW (2006). Chronic myeloid leukemia in 2006: a perspective. [Review]. Haematologica, 91(2), 152.
  26. Deininger M (2005). Resistance to imatinib: mechanisms and management. [Review]. J Natl Compr Canc Netw, 3(6), 757-68.
  27. Deininger M, Buchdunger E, Druker BJ (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. [Review]. Blood, 105(7), 2640-53.
  28. Deininger MW (2005). Management of early stage disease. [Review]. Hematology Am Soc Hematol Educ Program, 174-82.
  29. Loriaux M, Deininger M (2004). Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. [Review]. Leuk Lymphoma, 45(11), 2197-203.
  30. Silver RT, Bennett JM, Deininger M, Feldman E, Rafii S, Silverstein RL, Solberg LA, Spivak JL (2004). The second international congress on myeloproliferative and myelodysplastic syndromes. [Review]. Leuk Res, 28(9), 979-85.
  31. Deininger MW (2004). Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia. [Review]. J Cancer Res Clin Oncol, 130(2), 59-72.
  32. Deininger MW, Druker BJ (2003). Specific targeted therapy of chronic myelogenous leukemia with imatinib. [Review]. Pharmacol Rev, 55(3), 401-23.
  33. Deininger MW, OBrien SG, Ford JM, Druker BJ (2003). Practical management of patients with chronic myeloid leukemia receiving imatinib. [Review]. J Clin Oncol, 21(8), 1637-47.
  34. Deininger MW (2003). Cytogenetic studies in patients on imatinib. [Review]. Semin Hematol, 40(2 Suppl 2), 50-5.
  35. OBrien SG, Deininger MW (2003). Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. [Review]. Semin Hematol, 40(2 Suppl 2), 26-30.
  36. Deininger M, Niederwieser D (2002). [Molecular therapy of chronic myeloid leukemia--a new era in the treatment of malignant diseases]. [Review]. Med Klin (Munich), 97 Suppl 1, 1.
  37. Deininger MW, Goldman JM, Melo JV (2000). The molecular biology of chronic myeloid leukemia. [Review]. Blood, 96(10), 3343-56.

Book Chapter

  1. Deininger MW, John P Greer, Daniel A Arber, Bertil Glader, Alan F List, Robert T Means Jr, Frizos Paraskevas, George M Rodgers (2013). Chronic Myeloid Leukemia. In Wintrobe’s Clinical Hematology (13th). Wolters Kluwer.
  2. Agarwal A, Byrd J, Deininger MW (2012). Chronic Leukemias. In DeVita V, Lawrence TS, Rosenberg SA (Eds.). (Eds.), Cancer: Principles & Practice of Oncology: Primer of the Molecular Biology. Wolters Kluwer.
  3. Shenoy S, Deininger MW (2012). Myeloproliferative and Myelodysplastic Disorders in Children, Adolescents and Young Adults. In Cairo MS and Perkins SL (Eds.). (Eds.), Hematological Malignancies in Children, Adolescents and Young Adults. World Scientific Publishing.
  4. OHare T, Eide CA, Deininger MW (2009). A new generation of drugs in cancer treatment: molecularly targeted therapies. In Stein G, Pardee A (Eds.), The Biology and Treatment of Cancer: Understanding Cancer (pp. 193-222). Hoboken, NJ: John Wiley & Sons, Inc.
  5. La Rosee P, Deininger MW (2008). Cytogenetics and Molecular Biology of Chronic Myeloid Leukaemia. In Mughal T, Goldman JM (Eds.), Chronic Myeloproliferative Disorders (pp. 17-43). Informa Healthcare.
  6. Deininger MW, Cortes J Eds (2008). Chronic myeloid leukemia. CRC Press.
  7. Deininger MW, Druker BJ (2007). Drug Therapy of Chronic Myeloid Leukaemia. In Fojo T (Ed.), Chemotherapy Sourcebook. Lippincot.
  8. Deininger MW (2007). Chronic myeloid leukemia: molecular biology, pathology and cytogenetics. In Sekeres MA, Kalaycio ME, Bolwell BJ (Eds.), Clinical Malignant Hematology. McGraw-Hill.
  9. Deininger MW (2007). Tyrosine Kinase Inhibitors. In Gewirtz E (Ed.), Apoptosis and Senescence in Cancer. McGraw Hill.
  10. Deininger MW (2006). Signal Transduction Inhibitors in Chronic Myeloid Leukemia. In Melo, Goldman (Eds.), Myeloproliferative Disorders (pp. 75-109). Berlin&Heidelberg: Springer.
  11. Deininger MW (2006). BCR-ABL as a molecular target. In Deininger MW, Cortes J (Eds.), Chronic Myeloid Leukemia (pp. 1-12). New York and Oxford: Informa.
  12. Deininger MW (2004). Clinical Applications. In Stein G, Pardee A (Eds.), Cell cycle and Growth control: Biomolecular Regulation and Cancer (pp. 660-707). New York: Wiley&Sons.
  13. Deininger MW (2002). Grundlagen der Therapie mit Imatinib Mesilat. In Fischer T (Ed.), Der Signalhemmer Imatinib Mesilat (pp. 12-29). Bremen: Uni-Med Verlag.

Case Report

  1. Ernst T, Score J, Deininger M, Hidalgo-Curtis C, Lackie P, Ershler WB, Goldman JM, Cross NC, Grand F (2011). Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia. Br J Haematol, 153(1), 43-6.

Editorial

  1. Mughal TI, Deininger MW, Kucine N, Saglio G, Van Etten RA (2019). Children and Adolescents with Chronic Myeloproliferative Neoplasms: Still an Unmet Biological and Clinical Need? Hemasphere, 3(4), e283.
  2. Carella AM, Branford S, Deininger M, Mahon FX, Saglio G, Eiring A, Khorashad J, OHare T, Goldman JM (2013). What challenges remain in chronic myeloid leukemia research? Pediatrics and Neonatal Care, 98(8), 1168-72.
  3. Khorashad JS, Deininger MW, OHare T (2013). New concepts for CML clonality. Pediatrics and Neonatal Care, 4(1), 7-8.
  4. OHare T, Eide CA, Deininger MW (2008). Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemia. Utah Special Educator, 100(13), 908-9.
  5. OHare T, Walters DK, Deininger MW, Druker BJ (2005). AMN107: tightening the grip of imatinib. Cancer Cell, 7(2), 117-9.
  6. Deininger MW, Druker BJ (2004). SRCircumventing imatinib resistance. Cancer Cell, 6(2), 108-10.
  7. Deininger M (2004). Src kinases in Ph+ lymphoblastic leukemia. Nat Genet, 36(5), 440-1.

Letter

  1. Roberts KE, Deininger MW, Hildebrandt GC, Gackenbach BK, Krem MM (2020). Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia. [Letter to the editor]. Leuk Lymphoma, 61(14), 3507-3510.
  2. Zhao H, Mendenhall M, Deininger MW (2020). Imatinib is not a potent anti-SARS-CoV-2 drug. [Letter to the editor]. Leukemia, 34(11), 3085-3087.
  3. Than H, Pomicter AD, Yan D, Beaver LP, Eiring AM, Heaton WL, Senina A, Clair PM, Shacham S, Mason CC, Hare TO, Deininger MW (2020). Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells. [Letter to the editor]. Leukemia, 34(6), 1679-1683.
  4. Tantravahi SK, Schumacher J, Burt RW, Kelley TW, Deininger MW (2014). Systemic mastocytosis in a patient with Cowden syndrome. [Letter to the editor]. Am J Hematol, 89(12), 1154.
  5. Shah NP, Talpaz M, Deininger MW, Mauro MJ, Flinn IW, Bixby D, Lustgarten S, Gozgit JM, Clackson T, Turner CD, Haluska FG, Kantarjian H, Cortes JE (2013). Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. [Letter to the editor]. Br J Haematol, 162(4), 548-52.
  6. Demehri S, OHare T, Eide CA, Smith CA, Tyner JW, Druker BJ, Deininger MW (2010). The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis. [Letter to the editor]. Leukemia, 24(1), 226-9.
  7. Mller C, Hennig E, Franke C, Krahl R, Leiblein S, Niederwieser D, Deininger MW (2002). The BCR/ABL-extra signal fluorescence in situ hybridization system reliably detects deletions upstream of the ABL locus: implications for reporting of results and followup of chronic myelogenous leukemia patients. [Letter to the editor]. Cancer Genet Cytogenet, 136(2), 149-50.
  8. Reid AG, Huntly BJ, Hennig E, Niederwieser D, Campbell LJ, Bown N, Telford N, Walker H, Grace CD, Deininger MW, Green AR, Nacheva EP (2002). Deletions of the derivative chromosome 9 do not account for the poor prognosis associated with Philadelphia-positive acute lymphoblastic leukemia. [Letter to the editor]. Blood, 99(6), 2274-5.

Abstract

  1. Andersen EF, Salama ME, Sederberg MC, Toydemir RM, Kovacsovics TJ, Parker CJ, Rodgers GM, Shami PJ, Deininger MW, South ST (2015). Evaluating the Clinical Utility of Peripheral Blood Samples for Molecular Evaluation of MDS by SNP-A [Abstract]. Leukemia Research, 39(S1), S72.
  2. Kim DW, Antolini L, Mahon FX, Guilhot F, Deininger M, Saglio G, Nagler A, Rambaldi A, Morra E, Abruzzese E, Di Raimondo F, le Coutre P, Monroy RH, Durosinmi MA, Leeksma O, Pane F, Miglietta S, Kweon I, Reiffers J, Valsecchi MG, Gambacorti-Passerini C (Nov 2009). Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 2199.
  3. Cortes J, Talpaz M, Deininger M, Shah N, Flinn IW, Mauro MJ, OHare T, Spinos N, Hu S, Berk L, Narasimhan N, Rivera VM, Clackson T, Haluska F, Kantarjian HM (Nov 2009). A Phase 1 Trial of Oral AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Other Hematologic Malignancies: First Results of Safety and Clinical Activity against T315I and Resistant Mutations (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 643.
  4. Tyner JW, Fletcher L, Yang W, Oh ST, Gotlib JR, Deininger MW, Druker BJ, Loriaux M (Nov 2009). Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 708.
  5. Lunghi P, Mazzera L, Corradi A, Cantoni AM, Jottini S, Lombardi G, Ricca M, Arienti D, Rizzoli V, Deininger MW, Bonati A (Nov 2009). Arsenic Trioxide (ATO) Interacts Synergistically with MEK Inhibitors to Induce Apoptosis in STI571-Resistant Bcr-Abl Mutants (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 2177.
  6. Bhatia R, Snyder DS, Lin A, Arceo J, Seymour L, Deininger M, Radich J, Blanchard S, Forman S (Nov 2009). A Phase I Study of the HDAC Inhibitor LBH589 in Combination with Imatinib for Patients with CML in Cytogenetic Remission with Residual Disease Detectable by Q-PCR (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 2194.
  7. Tyner JW, Loriaux M, Willis SG, Chang BH, Bicocca VT, Oh ST, Hollink I, Segers S, DenBoer ML, van den Heuvel-Eibrink MM, Zwaan CM, Gotlib JR, Deininger M, Druker BJ (Nov 2009). RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 3978.
  8. Deininger M, Mahon FX, Guilhot F, Saglio G, le Coutre P, Nagler A, DEmilio A, Stagno F, Morra E, Piccin A, Assouline SE, Abruzzese E, Santini V, Pane F, Giraldo P, Antolini L, Valsecchi MG, Gambacorti-Passerini C (Nov 2009). Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 1108.
  9. Deininger M, OBrien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Hatfield AK, Mone M, Filian J, Reynolds J, Gathmann I, Larson RA, Druker BJ (Nov 2009). International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 1126.
  10. Khoury HJ, Mauro MJ, Matloub Y, Chen T, Bahceci E, Deininger M (Nov 2009). 9. Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 1128.
  11. Mackenzie R, Snead J, VanDyke J, Deininger M (Nov 2009). Defining Extrinsic Survival Pathways in CML Progenitor Cells (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 941.
  12. Aichberger KJ, Fleischman AG, Doratotaj S, Bumm TGP, Silver RT, Deloughery TG, Pahl HL, Druker BJ, Burns CJ, Deininger M (Nov 2009). Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 2917.
  13. McWeeney S, Yochum G, Pemberton LC, Loriaux M, Vartanian K, Willis SG, Wilmot B, Turpaz Y, Pillai R, Mac partlin M, Snead J, Druker BJ, OBrien SG, Melo JV, Lange T, Harrington C, Deininger M (Nov 2009). A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 508.
  14. Agarwal A, Mackenzie R, LaTocha D, Vasudevan K, Firpo E, Loriaux M, Nakayama K, Druker BJ, Roberts JM, Deininger M (Nov 2009). The Oncogenic Role of Tumor Suppressor Protein p27 in Ph+ Chronic Myeloid Leukemia (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 114, 3276.
  15. Gambacorti-Passerini C, Kim D, Mahon F, Saglio G, Pane F, Guilhot F, Deininger MW, Nagler A, Rambaldi A, Morra E, Antolini L, Kweon I, Reiffers J, Tornaghi L, Valsecchi MG (Nov 2008). Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 1099.
  16. Press RD, Willis SG, Laudadio J, Mauro MJ, Deininger MW (Nov 2008). Determining the Rise in BCR-ABL RNA That Optimally Predicts a Kinase Domain Mutation in Patients with CML on Imatinib (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 1108.
  17. OHare T, Eide CA, Adrian LT, Rivera VM, Shakespeare WC, Clackson T, Deininger MW, Druker BJ (Nov 2008). Complete Suppression of in Vitro Resistance by AP24534, a Pan-BCR-ABL Inhibitor (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 726.
  18. Corbin AS, OHare T, Druker BJ, Deininger MW (Nov 2008). Suppression of CML Progenitor but Not CML Stem Cell Growth Requires Dual Inhibition of BCR-ABL and KIT (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 190.
  19. Tyner JW, Erickson H, Oh S, Gotlib JR, Deininger MW, Druker BJ, Loriaux M (Nov 2008). Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 2519.
  20. Deininger MW, Mauro MJ, Matloub Y, Sinha R, Ploughman L, Liu D, Radich J (Nov 2008). Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 3236.
  21. Tyner JW, Loriaux M, Willis SG, Chang B, Bicocca VT, Oh S, Hollink I, Segers S, den Boer ML, Zwaan CM, Gotlib JR, Deininger MW, Druker BJ (Nov 2008). RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 758.
  22. Bumm TGP, Tyner JW, Deininger J, Loriaux M, VanDyke J, Druker BJ, Burns CJ, Fantino E, Deininger MW (Nov 2008). Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 112, 856.
  23. Pelz-Ackermann O, Deininger MW, Cross M, Wildenberger K, Krahl R, Wang S, Al-Ali HK, Niederwieser DW, Lange T (Nov 2007). BCR-ABL Kinase Domain Mutations in the P-Loop and at Imatinib Contact Sites in CML Patients with Imatinib Resistance Are Associated with Higher Maximum Imatinib Doses (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 2918.
  24. Sherbenou DW, Hantschel OJ, Turaga L, Mag IK, Willis S, Bumm T, Press RD, Superti-Furga G, Druker BJ, Deininger MW (Nov 2007). Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 2936.
  25. Bumm TGP, VanDyke J, Loriaux M, Gendron C, Wood LG, Druker BJ, Deininger MW (Nov 2007). TNF-alpha Plays a Crucial Role in the JAK2-V617F Induced Myeloproliferative Disorder (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 675.
  26. Loriaux M, Levine R, Tyner J, Frohling S, Scholl C, Stoffregen E, Wernig G, Erickson H, Eide C, Berger R, Bernard O, Griffin J, Stone R, Meyerson M, Heinrich M, Deininger M, Gilliland G, Druker B (Nov 2007). High-Throughput Sequence Analysis of the Tyrosine Kinome in Acute Myeloid Leukemia (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 886.
  27. Mauro MJ, Press RD, Deininger MW, Druker BJ (Nov 2007). BCR-ABL Transcript Levels at Time of Complete Cytogenetic Remission Achieved after Salvage with Dasatinib or Nilotinib (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 1945.
  28. Laudadio J, Deininger MW, Mauro MJ, Druker BJ, Press RD (Nov 2007). An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Three CML Patients Undergoing Kinase Inhibitor Therapy (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 1953.
  29. Frohling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Dohner H, Dohner K, Ebert BL, Teckie S, Golub TR, Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker MJ, Gilliland DG (Nov 2007). Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 208.
  30. Jeffrey W Tyner, Stephanie Willis, Michael WN Deininger, and Brian J Druker (Nov 2007). RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 208.
  31. Agarwal A, Eide CA, Harlow A, Tyner JW, Mauro MJ, Corless CL, Heinrich MC, Druker BJ, Deininger MW (Nov 2007). An Activating KRAS Mutation in Imatinib Resistant Chronic Myeloid Leukemia (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 1006.
  32. McWeeney SK, Pemberton LC, Harrington CA, Druker BJ, Deininger MW (Nov 2007). A Transcriptomal Profile for Predicting Complete Cytogenetic Response (CCR) in Chronic Phase CML Patients Treated with Imatinib (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 1007.
  33. MacPartlin M, Honigberg LA, Druker BJ, Deininger MW (Nov 2007). Bruton's Tyrosine Kinase (BTK) Is Not Required for BCR-ABL-Mediated Transformation of Hematopoietic Cells (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 1015.
  34. Bumm TGP, Newell AH, Oost J, VanDyke J, Olson SB, Druker BJ, Deininger MW (Nov 2007). Chromosomal Abnormalities in the Early Stem Cell Population of CML Patients in Complete Cytogenetic Remission (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 36.
  35. OHare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, Holme K, Jessen KA, Tang C, Lewis HA, Romero RD, Burley SK, Deininger MW (Nov 2007). SGX70393 Inhibits Bcr-AblT315I In Vitro and In Vivo and Completely Suppresses Resistance When Combined with Nilotinib or Dasatinib (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 535.
  36. Tyner JW, Eide CA, Stoffregen EP, Loriaux M, Willis SG, Gattermann N, Kovacsovics T, Druker BJ, Deininger MW (Nov 2006). Identification of Tyrosine Kinase Mutations by Large-Scale DNA Sequencing in Patients with Chronic Myelomonocytic Leukemia/Atypical Chronic Myeloid Leukemia (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 3606.
  37. OHare T, Eide CA, Tyner JW, Wong MJ, Smith CA, Corbin AS, Buchanan S, Jessen KA, Tang C, Holme K, Burley SK, Deininger MW (Nov 2006). Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393 (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 1373.
  38. MacPartlin M, OHare T, Bumm T, Goss V, Lee K, Corbin A, Stoffregen EA, Smith C, Johnson K, Moseson E, Griswold I, Wood L, Polakiewicz R, Druker BJ, Deininger MW (Nov 2006). Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 4796.
  39. Agarwal A, Bumm TGP, Corbin A, OHare T, Loriaux M, Willis SG, Deininger J, Druker BJ, Deininger MW (Nov 2006). The F-Box Protein Skp2 Regulates Expression of p27 in BCR-ABL Transformed Cell Lines and Is Required for Induction of Myeloproliferative Disease in a Murine Model (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 742.
  40. Nardi V, Raz T, Chao X, Wu CJ, Stone R, Galinsky I, Wadleigh M, Deininger MW, Church G, Zhu J, Daley GQ (Nov 2006). Monitoring Imatinib Resistance with a "Polony" Assay: Towards Tailored Therapy of Chronic Myelogenous Leukemia (CML) (also presented orally) [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 837.
  41. Press RD, Willis S, Rempfer C, Mauro MJ, Druker BJ, Deininger MW (Nov 2006). A Half-Log Increase in Quantitative RT-PCR for BCR-ABL (RQ-PCR) as a Trigger for Kinase Domain Mutation Analysis (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 2152.
  42. Sherbenou DW, Hantschel O, Willis S, Press RD, Druker BJ, Superti-Furga G, Deininger MW (Nov 2006). A Subset of Chronic Myeloid Leukemia (CML) Patients on ABL Kinase Inhibitor Therapy Develop Point Mutations outside the BCR-ABL Kinase Domain That Decrease Drug Sensitivity and May Have a Role in Disease Progression (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 2188.
  43. Pelz-Ackermann O, Deininger MW, Cross M, Kovacs I, Guenther C, Krohn K, Wang S, Al-Ali HK, Niederwieser DW, Lange T (Nov 2006). First Results of a New PCR-Based Approach for a Sensitive and Quantitative Monitoring of BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia (also presented poster) [Abstract]. Blood (ASH Annual Meeting Abstracts), 108, 2191.

Other

  1. Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M (2019). Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44]. Leuk Res (81, p. 105). England.

Patent

  1. (2017). SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRAZINE AND IMIDAZO[1,2-a]PYRAZIN SERIES COMPOUNDS AS SIRTUIN5 (SIRT5) MODULATORS IN TREATING CANCER.